AI assistant
NovoCure Ltd — Director's Dealing 2019
Aug 1, 2019
31949_dirs_2019-08-01_035e251d-6773-40a5-983f-34a212c74dee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2019-07-30
Reporting Person: DOYLE WILLIAM F (Director, Executive Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-07-30 | Restricted Stock Units | A | 6002 | $0.00 | Acquired | 852465 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-07-30 | Options to Buy Ordinary Shares | $83.30 | A | 10412 | Acquired | 2029-07-30 | Ordinary Shares (10412) | Direct |
Footnotes
F1: These equity awards were granted to Mr. Doyle in recognition of his accomplishments related to Medicare coverage and pricing.
F2: One-third of these restricted stock units are scheduled to vest on each of July 30, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates.
F3: Options to buy 10,412 ordinary shares will vest and become exercisable in equal installments on each of July 30, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.